常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.59/-1.37
|
|
企業價值
436.40M
|
| 資產負債 |
|
每股賬面淨值
1.00
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
73.95M
|
|
每股收益
0.16
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 08:34 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications. |

3.9 
